Elevated MRNA Levels of AURKA, CDC20 and TPX2 Are Associated with Poor Prognosis of Smoking Related Lung Adenocarcinoma Using Bioinformatics Analysis

Overview

Journal Int J Med Sci

Specialty General Medicine

Date 2018 Dec 28

PMID 30588191

Citations 41

Authors

Meng-Yu Zhang

Xiao-Xia Liu

Hao Li

Rui Li

Xiao Liu

Yi-Qing Qu

Affiliations

Soon will be listed here.

Abstract

Adenocarcinoma is a very common pathological subtype for lung cancer. We aimed to identify the gene signature associated with the prognosis of smoking related lung adenocarcinoma using bioinformatics analysis. A total of five gene expression profiles (GSE31210, GSE32863, GSE40791, GSE43458 and GSE75037) have been identified from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were analyzed using GEO2R software and functional and pathway enrichment analysis. Furthermore, the overall survival (OS) and recurrence-free survival (RFS) have been validated using an independent cohort from the Cancer Genome Atlas (TCGA) database. We identified a total of 58 DEGs which mainly enriched in ECM-receptor interaction, platelet activation and PPAR signaling pathway. Then according to the enrichment analysis results, we selected three genes ( and ) for their roles in regulating tumor cell cycle and cell division. The results showed that the hazard ratio (HR) of the mRNA expression of for OS was 1.588 with (1.127-2.237) 95% confidence interval (CI) (P=0.009). The mRNA levels of (HR 1.530, 95% CI 1.086-2.115, P=0.016) and (HR 1.777, 95%CI 1.262-2.503, P=0.001) were also significantly associated with the OS. Expression of these three genes were not associated with RFS, suggesting that there might be many factors affect RFS. The mRNA signature of AURKA, CDC20 and TPX2 were potential biomarkers for predicting poor prognosis of smoking related lung adenocarcinoma.

Citing Articles

A comprehensive in silico analysis and experimental validation of miRNAs capable of discriminating between lung adenocarcinoma and squamous cell carcinoma.

Javanmardifard Z, Rahmani S, Bayat H, Mirtavoos-Mahyari H, Ghanei M, Mowla S Front Genet. 2024; 15:1419099.

PMID: 39381140 PMC: 11460580. DOI: 10.3389/fgene.2024.1419099.

Assessment of AURKA expression and prognosis prediction in lung adenocarcinoma using machine learning-based pathomics signature.

Bai C, Sun Y, Zhang X, Zuo Z Heliyon. 2024; 10(12):e33107.

PMID: 39022022 PMC: 11253280. DOI: 10.1016/j.heliyon.2024.e33107.

Exploring gene regulatory interaction networks and predicting therapeutic molecules for hypopharyngeal cancer and EGFR-mutated lung adenocarcinoma.

Bhattacharjya A, Islam M, Uddin M, Talukder M, Azad A, Aryal S FEBS Open Bio. 2024; 14(7):1166-1191.

PMID: 38783639 PMC: 11216941. DOI: 10.1002/2211-5463.13807.

A novel prognostic signature based on smoking-associated genes for predicting prognosis and immune microenvironment in NSCLC smokers.

Li Q, Wang T, Tang Y, Zou X, Shen Z, Tang Z Cancer Cell Int. 2024; 24(1):171.

PMID: 38750571 PMC: 11094918. DOI: 10.1186/s12935-024-03347-9.

Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review.

Mao X, Lee N, Saad S, Fong I Transl Lung Cancer Res. 2024; 13(2):375-397.

PMID: 38496700 PMC: 10938103. DOI: 10.21037/tlcr-23-742.

References

Landi M, Dracheva T, Rotunno M, Figueroa J, Liu H, Dasgupta A . Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One. 2008; 3(2):e1651. PMC: 2249927. DOI: 10.1371/journal.pone.0001651. View

Malumbres M, Barbacid M . Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9(3):153-66. DOI: 10.1038/nrc2602. View

Shariat S, Lotan Y, Vickers A, Karakiewicz P, Schmitz-Drager B, Goebell P . Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol. 2010; 28(4):389-400. PMC: 3407571. DOI: 10.1016/j.urolonc.2010.02.011. View

Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R . Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res. 2011; 72(1):100-11. DOI: 10.1158/0008-5472.CAN-11-1403. View

Chang D, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese J . Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. J Hematol Oncol. 2012; 5:15. PMC: 3350393. DOI: 10.1186/1756-8722-5-15. View

Kato T, Daigo Y, Aragaki M, Ishikawa K, Sato M, Kaji M . Overexpression of CDC20 predicts poor prognosis in primary non-small cell lung cancer patients. J Surg Oncol. 2012; 106(4):423-30. DOI: 10.1002/jso.23109. View

Tabas-Madrid D, Nogales-Cadenas R, Pascual-Montano A . GeneCodis3: a non-redundant and modular enrichment analysis tool for functional genomics. Nucleic Acids Res. 2012; 40(Web Server issue):W478-83. PMC: 3394297. DOI: 10.1093/nar/gks402. View

Selamat S, Chung B, Girard L, Zhang W, Zhang Y, Campan M . Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res. 2012; 22(7):1197-211. PMC: 3396362. DOI: 10.1101/gr.132662.111. View

Lohr M, Kollmann C, Freis E, Hellwig B, Hengstler J, Ickstadt K . Optimal strategies for sequential validation of significant features from high-dimensional genomic data. J Toxicol Environ Health A. 2012; 75(8-10):447-60. DOI: 10.1080/15287394.2012.674912. View

10.

Imielinski M, Berger A, Hammerman P, Hernandez B, Pugh T, Hodis E . Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012; 150(6):1107-20. PMC: 3557932. DOI: 10.1016/j.cell.2012.08.029. View

11.

Govindan R, Ding L, Griffith M, Subramanian J, Dees N, Kanchi K . Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012; 150(6):1121-34. PMC: 3656590. DOI: 10.1016/j.cell.2012.08.024. View

12.

Zhang Y, Foreman O, Wigle D, Kosari F, Vasmatzis G, Salisbury J . USP44 regulates centrosome positioning to prevent aneuploidy and suppress tumorigenesis. J Clin Invest. 2012; 122(12):4362-74. PMC: 3533537. DOI: 10.1172/JCI63084. View

13.

Saintigny P, Massarelli E, Lin S, Ahn Y, Chen Y, Goswami S . CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res. 2012; 73(2):571-82. PMC: 3548940. DOI: 10.1158/0008-5472.CAN-12-0263. View

14.

Li L, Yang G, Ren C, Tanimoto R, Hirayama T, Wang J . Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2. Mol Oncol. 2013; 7(3):484-96. PMC: 3907183. DOI: 10.1016/j.molonc.2012.12.005. View

15.

Chen T, Liu Y, Huang Y, Yeh Y, Chou T, Wu Y . Protein phosphorylation profiling using an in situ proximity ligation assay: phosphorylation of AURKA-elicited EGFR-Thr654 and EGFR-Ser1046 in lung cancer cells. PLoS One. 2013; 8(3):e55657. PMC: 3592865. DOI: 10.1371/journal.pone.0055657. View

16.

Kabbout M, Garcia M, Fujimoto J, Liu D, Woods D, Chow C . ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer. Clin Cancer Res. 2013; 19(13):3383-95. PMC: 3846434. DOI: 10.1158/1078-0432.CCR-13-0341. View

17.

Choi J, Kim Y, Lee J, Kim Y . High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer. Virchows Arch. 2013; 463(5):681-7. DOI: 10.1007/s00428-013-1473-6. View

18.

Moura I, Delgado M, Silva P, Lopes C, do Amaral J, Monteiro L . High CDC20 expression is associated with poor prognosis in oral squamous cell carcinoma. J Oral Pathol Med. 2013; 43(3):225-31. DOI: 10.1111/jop.12115. View

19.

Goldenson B, Crispino J . The aurora kinases in cell cycle and leukemia. Oncogene. 2014; 34(5):537-45. PMC: 4167158. DOI: 10.1038/onc.2014.14. View

20.

Li J, Gao J, DU J, Huang Z, Wei L . Increased CDC20 expression is associated with development and progression of hepatocellular carcinoma. Int J Oncol. 2014; 45(4):1547-55. DOI: 10.3892/ijo.2014.2559. View